A randomized, double blind placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of QBW251 in healthy subjects and multiple doses in cystic fibrosis patients
Phase of Trial: Phase I/II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs QBW 251 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Novartis
- 29 Feb 2016 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 10 Mar 2015 Planned End Date changed from 1 Jan 2016 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 10 Mar 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Oct 2015 as reported by ClinicalTrials.gov record.